加载中
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
前收盘价
US$29.48
−US$0.99 · -3.25%
盘后
US$29.48
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
日内区间
当前US$29.48
52周区间
当前US$29.48
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
33
偏贵
情绪
53
多空交织
风险
31
中等风险
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
日内区间
当前US$29.48
52周区间
当前US$29.48
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 销货成本 | 40.9万 USD | — | — | — | — |
| 毛利 | −40.9万 USD | — | — | — | — |
| 研究与开发 | 4.57亿 USD | 3.61亿 USD | 2.13亿 USD | 1.6亿 USD | 1.02亿 USD |
| 销售、一般及管理费用 | 7624.2万 USD | 7723.5万 USD | 5728.1万 USD | 4801.9万 USD | 5422.5万 USD |
| 营业费用 | 5.33亿 USD | 4.38亿 USD | 2.7亿 USD | 2.08亿 USD | 1.56亿 USD |
| 利息收入 | 2533万 USD | 2473.2万 USD | 2494.8万 USD | 757.8万 USD | — |
| 利息支出 | — | — | — | 1248.2万 USD | — |
| 折旧和摊销 | 40.9万 USD | 37.7万 USD | 23.1万 USD | 19.3万 USD | 12.6万 USD |
| 营业利润 | −5.33亿 USD | −4.38亿 USD | −2.7亿 USD | −2.08亿 USD | −1.56亿 USD |
| 净利润 | −5.06亿 USD | −4.14亿 USD | −2.59亿 USD | −2.11亿 USD | −1.57亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$40.00
上涨空间 35.69%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.06亿0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB7708.42万0.04%1853亿 USD0.03%US$288.16-0.46%
iShares Russell 2000 ETFIWM6917.25万0.09%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI6321.45万0.64%98.74亿 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap Growth ETFVBK4436.92万0.10%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF3662.12万0.04%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO2431.99万0.17%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO2002.07万0.11%180亿 USD0.06%US$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
